News

Biotech's Boom Suffers a Setback in March April 01, 2014 | Press Release

Investors Flock to Biotech March 03, 2014 | Press Release

Biotech IPOs Off to a Strong Start in 2014 February 03, 2014 | Press Release

  See all News
 
Sign up for a free subscription to The Burrill Weekly Brief 
Sign up to receive email notifications about our upcoming events and news.



Anton Gueth

Senior Advisor

Mr. Gueth began his management career in business and alliance development over 20 years ago at Eli Lilly and Company. His global experience spans the U.S., Europe, the Middle East and Africa. Before joining Burrill Securities, Mr. Gueth was an independent consultant for pharmaceutical and biotechnology clients in the areas of licensing, early-stage financing and alliance management. His clients included Baxter, Amgen, Boehringer Ingelheim, Schering-Plough and Schering AG, among others. While at Lilly, Mr. Gueth held multiple positions of increasing responsibility, concluding as Director of Alliance Management. In this role he led Lilly’s efforts to become “the pharmaceutical partner of choice”. Mr. Gueth is a member of the board of directors of Antares Pharma. He is also on the board of the California chapter of the American Liver Foundation. An author and lecturer, Mr. Gueth has contributed to industry reports from In Vivo and Ernst and Young as well as business texts on strategic alliances. Mr. Gueth received his master’s degree in public affairs from Indiana University and an M.S. in agricultural economics from Justus Liebig University in Germany.